While glucosamine has long been associated with knees and joints as well as pain relief, new research is looking into a much more surprising area: how this commonly used supplement affects the brain once inside it.
An experiment done at the University of Florida linked glucosamine usage with worsening dementia in patients suffering from mild cognitive impairment (MCI). In addition, the researchers have found evidence in mice and human brains showing changes in the cellular mechanism responsible for attaching sugar molecules to proteins.
While these results, reported in Nature Metabolism, do not show that the supplement causes dementia or accelerates Alzheimer's progression, the researchers' health record analysis could only identify relationships in the data, not conclude causation.
However, these three types of research combined have provided researchers with something that deserves investigation.
A familiar joint supplement turns up in dementia research
Glucosamine is an organic compound responsible for the synthesis of substances that occur in cartilage. Moreover, it is available on the counter market as a supplement. In their research, scientists at the University of Florida were interested in finding out if its widespread usage can affect the occurrence of Alzheimer’s disease and related dementias (ADRD).
With the help of Dr Yi Guo and Jiang Bian, they studied electronic health records of UF Health from 2012 to 2024 using artificial intelligence methods.
The analysis included people diagnosed with either MCI or ADRD. Among the patients studied, about 8% reported using glucosamine.
This was equivalent to 2,750 individuals suffering from MCI and 1,896 individuals with ADRD.
Taking into consideration various factors such as age and demographics, the scientists concluded that the use of glucosamine is linked to a 25% increased risk of progressing from MCI to dementia.
As for the individuals suffering from ADRD, their risk of death was 25% higher if they used glucosamine. There was no association between the use of glucosamine and death in MCI patients.
The numbers may seem impressive, but they require special consideration.
People who take glucosamine can differ from non-users in ways that a retrospective health-record study cannot fully capture.
The researchers themselves describe the findings as an association rather than proof that glucosamine is responsible for the outcomes.
The researchers found a possible metabolic clue
The study became more interesting when the team looked beyond patient records.
Researchers used spatial molecular technology developed in Ramon Sun's laboratory to examine changes in thousands of molecules within brain tissue. Their attention turned to a process known as O-GlcNAcylation , in which sugar molecules are attached to proteins.
This is a normal cellular process. Protein sugar tags can influence how proteins fold, where they move within cells and how they function.
The problem, according to the researchers, is that this system appeared to be excessively active in Alzheimer's-affected brains.
Glucosamine can cross the blood-brain barrier and enter biochemical pathways involved in the production of these sugar structures. That gave the researchers a possible explanation for the association seen in the health records.
It does not mean that glucosamine inevitably produces harmful effects in the brain. Instead, the researchers propose that its effects could depend on the metabolic environment of the person taking it.
A healthy brain and a brain already affected by Alzheimer's-related changes may therefore respond differently to the same compound.
Matt Gentry, a study co-author and chair of UF's Department of Biochemistry and Molecular Biology, said the electronic health-record results raise a clinical question that needs further investigation.
Mouse experiments added another piece to the puzzle
The researchers then tested their hypothesis in genetically modified mice used to model Alzheimer's disease.
When the animals were given glucosamine, the researchers observed increased sugar attachment to proteins inside cells. The treated mice also showed greater problems with social memory, a form of recognition memory in which animals distinguish familiar individuals from unfamiliar ones.
The team then used a chemical treatment designed to reduce the sugar-attachment process.
When that pathway was suppressed, the mice showed improved memory performance.
That result gave the researchers a reason to look more closely at the metabolic pathway itself. Rather than simply being a chemical change that accompanies Alzheimer's, excessive protein sugar-tagging could potentially contribute to some of the biological problems associated with the disease.
The experiment, however, was performed in mice. The effects seen through the animal model may not necessarily be extrapolated to what occurs in humans consuming commercial glucosamine.
The results obtained through human records and those obtained through animal experiments are thus two different types of evidence, and not clinical proof that glucosamine hastens dementia.
Human brain tissue showed the same unusual pattern
The final part of the investigation involved human brain samples.
Working with neuropathologist Stefan Prokop, the researchers examined tissue from people with Alzheimer's disease supplied by the University of Florida's Neuromedicine Brain and Tissue Bank.
The Alzheimer's samples showed significantly higher levels of the same type of protein-sugar attachment compared with brain tissue from people without the disease.
That finding is important to the researchers because it places the metabolic change in actual human Alzheimer's tissue rather than limiting the observation to an experimental model.
The study therefore brings together three different lines of evidence: an association in electronic health records, experimental findings in mice and molecular changes detected in human Alzheimer's brain tissue.
Even so, the central question remains unanswered.
A controlled clinical trial would be needed to determine whether glucosamine itself causes faster cognitive decline, whether certain people are particularly susceptible, or whether the association in health records is partly explained by other factors.
For now, the study does not establish that people with MCI or dementia should stop taking glucosamine. It instead raises a question about a supplement that is already widely used and identifies a biological pathway that could warrant further study.
The findings also add to a broader shift in Alzheimer's research. Amyloid plaques and tau tangles remain major areas of investigation, but researchers are increasingly examining metabolism and other cellular processes that may influence how neurodegenerative disease develops.
If it is proven by human studies in the future to be true that there is an association between glucosamine, protein glycosylation and worsening of dementia, it will definitely revolutionise how researchers view the supplement.
For the time being, the findings remain fascinating, yet preliminary.
Frequently asked questions
1. Does glucosamine lead to dementia?Glucosamine is not proven to lead to dementia. The link established by researchers between taking glucosamine and the development of MCI into dementia cannot show causation since observational health record data cannot establish causal links.
2. What have University of Florida researchers discovered?
In people with MCI, there was a 25% greater chance of developing dementia, taking into account factors like age, gender, and other demographic factors. In addition, using glucosamine was associated with increased chances of mortality among those with ADRD.
3. Why do researchers study glucosamine and brain function?
Glucosamine crosses the blood-brain barrier and gets involved in metabolic processes related to adding sugar to proteins. It was found that there are increased rates of such processes in Alzheimer's disease patients.
4. Should one stop taking glucosamine based on this study?
The study does not provide the grounds for stopping taking glucosamine. Further research is required to establish whether the supplement impacts the development of dementia.
